Acute Coronary Syndrome Market is estimated to grow at 10.4% CAGR during forecast period 2017 to 2023

Global Acute Coronary Syndrome Market Research Report by Type (Unstable Angina, Nstemi), by Diagnosis (Blood Tests, Imaging, Stress Test), Treatment (Medication, Surgery), End-User (Hospitals & Clinics, Diagnostic Centers) - Global Forecast Till 2027

Acute Coronary Syndrome Market – Overview

The escalating stress levels have caused a sharp spike in the number of cases detected in relation to heart diseases. Market reports connected with the healthcare industry have been made accessible by Market Research Future who publishes reports on other sectors that have been currently published along with a report on this industry. The market is projected to develop with a CAGR of 10.4% in the forecast period.

Factors such as increased consumption of food that is saturated with fat, smoking, alcohol consumption and increasing prevalence of sedentary lifestyle are accredited with the rise in the cases of acute coronary syndrome cases in the forecast period. Growing research and development in the market is expected to reinforce the market expansion in the forecast period positively.

Segmental Analysis

The acute coronary syndrome market globally is segmented on the basis of treatment, diagnosis, type, and end-user. On the basis of end-user, the market is segmented into academic institutes, diagnostic centers, hospitals and clinics, and others. By type, the market is segmented into Non-ST-Elevation Myocardial Infarction (NSTEMI), ST-Elevation Myocardial Infarction (STEMI), unstable angina, and others. By diagnosis, the market is segmented into imaging, stress test, blood tests, and others. The imaging segment is further sub-segmented into Computerized Tomography (CT) angiogram, Myocardial Perfusion Imaging (MPI), coronary angiogram, echocardiogram, and others. On the basis of treatment, the market is segmented into surgery, medication, and others. The medication segment is sub-segmented into nitroglycerin, thrombolytics, antiplatelet drugs, beta blockers, surgery, statins, and others. The antiplatelet drugs segment is further segmented into clopidogrel, aspirin, prasugrel, and others. The beta blockers segment is moreover segmented into nadolol, metoprolol, and others. The statins segment is additionally segmented into simvastatin, atorvastatin, and others. The surgery segment is sub-segmented into coronary bypass surgery, angioplasty and stenting, and others.

Detailed Regional Analysis 

The regional analysis of the market states that the Americas dominates the global acute coronary syndrome market owing to the rising prevalence of coronary heart diseases and the presence of a well-developed healthcare sector within the region. Furthermore, growing healthcare expenditure and the presence of market players within the region boost the market. The European region comes in second in the acute coronary syndrome market owing to the growing availability of funds for research, a well-developed healthcare sector, and a huge patient population. The Asia Pacific region is the fastest rising region for the market owing to the incidence of emerging economies such as China, India, Australia, and others within the region.

Furthermore, a vast patient population, intensifying healthcare expenditure, and a quickly emerging healthcare sector that will fuel the market development in the forecast period. The Middle East and African region have the minimum share in the acute coronary syndrome market. This can be accredited to the low per capita health care spending and strict government policies, particularly within the African region. Conversely, the Middle East holds a chunk of the market owing to huge healthcare expenditure and a well-developed healthcare sector.

Competitive Analysis

The assortment available in terms of strategy creation and execution is shifting the expansion pace of the market. The gaps in the market are met owing  to the carrying out of proper supply chain strategies. Furthermore, the increase in new products and services will add more momentum to the market growth. The framework for development plans has fortified the market for feasible new entrants.

The strategic competitors in the acute coronary syndrome market are Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Boehringer Ingelheim International GmbH (Germany), Portola Pharmaceuticals, Inc. (U.S.), AbbVie Inc.  (U.S.), Bayer AG (Germany), AstraZeneca (U.K), Eli Lilly and Company (U.S.), Amgen Inc. (U.S.), Merck & Co., Inc. (U.S.), GlaxoSmithKline Plc. (U.K), Daiichi Sankyo Company, Limited (Japan), Sanofi (Paris), Novartis AG (Switzerland), and others.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/acute-coronary-syndrome-market-5782 

Industry Updates:

Sep 2018 The US Food and Drug Administration has accepted a supplemental Biologics License Application (sBLA) for alirocumab (Praluent Injection), a PCSK9 inhibitor. The sBLA proposes an upgrade to the Prescribing Information to include alirocumab as a treatment to reduce the overall risk of major adverse cardiovascular events (MACE). The applications included data from a placebo-controlled phase 3 trial of 18,924 patients who had acute coronary syndrome in the 1-12 before trial enrollment.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

All Posts
×

Almost done…

We just sent you an email. Please click the link in the email to confirm your subscription!

OKSubscriptions powered by Strikingly